Richard W Martin

List of Publications by Year
in descending order

27 papers	4,985 citations	331538 21 h-index	526166 27 g-index
27 all docs	27 docs citations	27 times ranked	3441 citing authors

#	Article	IF	Citations
1	<scp>Adipose€Derived</scp> Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis and Rheumatology, 2022, 74, 1399-1408.	2.9	9
2	Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards. Medical Decision Making, 2021, 41, 780-800.	1.2	28
3	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	5.2	348
4	Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Therapy in Rheumatoid Arthritis. Medical Decision Making, 2017, 37, 577-588.	1.2	9
5	Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. Journal of Immunology, 2016, 197, 2854-2863.	0.4	18
6	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. Journal of Rheumatology, 2015, 42, 2442-2447.	1.0	22
7	Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug. BMC Medical Informatics and Decision Making, 2013, 13, 89.	1.5	20
8	Providing information about options in patient decision aids. BMC Medical Informatics and Decision Making, 2013, 13, S4.	1.5	62
9	A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Research and Therapy, 2013, 15, R164.	1.6	100
10	Communicating the Risk of Side Effects to Rheumatic Patients. Rheumatic Disease Clinics of North America, 2012, 38, 653-662.	0.8	4
11	An experimental evaluation of patient decision aid design to communicate the effects of medications on the rate of progression of structural joint damage in rheumatoid arthritis. Patient Education and Counseling, 2012, 86, 329-334.	1.0	31
12	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care and Research, 2011, 63, 373-382.	1.5	58
13	MQX€503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. Arthritis and Rheumatism, 2009, 60, 870-877.	6.7	98
14	Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. Journal of Rheumatology, 2008, 35, 618-24.	1.0	37
15	Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11740-11745.	3.3	90
16	High-dose versus low-dose ?-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Seminars in Arthritis and Rheumatism, 2004, 33, 249-263.	1.6	49
17	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis and Rheumatism, 2002, 46, 1443-1450.	6.7	664
18	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism, 2002, 46, 2410-2420.	6.7	272

#	Article	IF	Citations
19	Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis and Rheumatism, 2002, 46, 2983-2989.	6.7	194
20	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis and Rheumatism, 2001, 44, 653-661.	6.7	96
21	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. Arthritis and Rheumatism, 2000, 43, 2445-2454.	6.7	252
22	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1586-1593.	13.9	1,776
23	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis and Rheumatism, 1999, 42, 1194-1203.	6.7	312
24	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 2372-2380.	6.7	96
25	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Arthritis and Rheumatism, 1998, 41, 670-677.	6.7	175
26	Eosinophilic Fasciitis Associated With Use of l-Tryptophan: A Case-Control Study and Comparison of Clinical and Histopathologic Features. Mayo Clinic Proceedings, 1991, 66, 892-898.	1.4	18
27	The Clinical Spectrum of the Eosinophilia-Myalgia Syndrome Associated with L-Tryptophan Ingestion. Annals of Internal Medicine, 1990, 113, 124.	2.0	147